Anti-Cancer/ Oncology API Products
探索する 抗がん/腫瘍 Products
アビラテロン酢酸エステル
抗がん/腫瘍
Adagrasib
抗がん/腫瘍
アパルタミド
抗がん/腫瘍
アザシチジン
抗がん/腫瘍
ベンダムスチン塩酸塩
抗がん/腫瘍
ボルテゾミブ
抗がん/腫瘍
カバジタキセル
抗がん/腫瘍
Cabozantinib HCl
抗がん/腫瘍
Cabozantinib S-Malate
抗がん/腫瘍
カペシタビン
抗がん/腫瘍
Carfilzomib
抗がん/腫瘍
Darolutamide
抗がん/腫瘍
ダサチニブ
抗がん/腫瘍
デシタビン
抗がん/腫瘍
Deucravacitinib
抗がん/腫瘍
エンザルタミド
抗がん/腫瘍
エリブリンメシル酸塩
抗がん/腫瘍
フォサプレピタント
抗がん/腫瘍
Fruquintinib
抗がん/腫瘍
Gemcitabine Hydrochloride
抗がん/腫瘍
Granisteron
抗がん/腫瘍
レナリドミド
抗がん/腫瘍
Lenvatinib Mesylate (Form C & MIBK Solvate)
抗がん/腫瘍
Lenvatinib Mesylate (Form-C)
抗がん/腫瘍
ロムスチン
抗がん/腫瘍
ミドスタウリン
抗がん/腫瘍
ニロチニブ塩酸塩
抗がん/腫瘍
Niraparib Tosylate
抗がん/腫瘍
Olaparib (Form A)
抗がん/腫瘍
パルボシクリブ
抗がん/腫瘍
Pazopanib
抗がん/腫瘍
ペメトレキセド二ナトリウム（七水和物）
抗がん/腫瘍
Pirtobrutinib
抗がん/腫瘍
ポマリドミド
抗がん/腫瘍
Relugolix
抗がん/腫瘍
Ripretinib
抗がん/腫瘍
Ritlecitinib
抗がん/腫瘍
Dr. Reddys Portfolio of Anti-cancer APIs
We manufacture our Anti-cancer APIs at cGMP API manufacturing facilities which are successfully inspected by international regulatory authorities such as the USFDA, EMEA, ANVISA, PMDA, and Health Canada.
Our team of process experts draws on their integrated understanding of IP, process development (API and formulation), and API manufacturing to ensure that by design, the process is lean, free from potential genotoxic impurities, and scalable to manufacture for early market entries. This is of particular importance to select the optimal synthesis route in the context of the IP situation. Other aspects are the solid-state forms and particle characteristics that are critical in formulation development.
We have incorporated sensitive and rigorous analytical methods to control the impurities at a specified level and extensively studied the flow properties, crystal size/shape, and morphology in accordance with future requirements. In addition, our APIs have been designed to address customized PSD requirements through size reduction and crystallization techniques, resulting in a high probability of successful formulation development.
USPs of our Anti-cancer APIs
- QbD approach for an efficient process & high-quality output
- Availability of APIs in various forms.
- cGMP API manufacturing facility - Successfully inspected by international regulatory authorities.
- GTIs & impurities are controlled below the TTC limit & ICH limits, respectively.
- Formulation dossier filed across all major markets.
- Regulatory filing available across the globe.
- Completely backward integrated on the Key starting materials to ensure uninterrupted supplies.
- Adequate capacity to meet the global demands.
- KSM suppliers with timely deliveries and adherence to stringent specifications.
- Process safety management guidelines are implemented to enable a sustainable product supply.
- IP-Compliant API that meets regulatory requirements.
Dr. Reddy, is well-positioned to meet the global demand for Anti-cancer/Oncology APIs. As for many of our APIs. the key starting materials (KW) are backward integrated today. We've also established strategic solid sourcing and logistics partnerships and work closely with our customers to successfully manage Me capacities of our manufacturing units ahead of launches.
To know more about our end-to-end solutions for Anti-cancer/Oncology APIs formulations and Dosage forms. Check out our board portfolio of Anti-cancer/Oncology APIs here (Link) (or) Contact us at [email protected]
探索する other Therapeutic categories.
Category-Oncology FAQ
- The oncology API market aims to share and reshape the flow of the pharmaceutical industry's demand.
- The global oncology API market is expected to exhibit strong growth from 2022 to 2026.
- The cancer API Market is expected to reach USD 1,48,545.23 Million by 2030 at 7.10% CAGR during the forecast period 2022-2030.
Oncology drugs are therapeutics used to treat cancer, a group of diseases caused by uncontrolled growth and division of abnormal cells. Oncology drugs include a range of different types of medications, such as chemotherapy agents, targeted therapies, immunotherapies, and hormone therapies.
- Thalidomide Analogues
- Alkalyting agents
- Androgen receptors
- Folate Analog Metabolic
- Nucleoside
- Metabolic
- Microtubule
Alkylating agents - cross-linking of DNA strands, inhibiting DNA replication and RNA transcription. Some antimetabolites - Interfere with DNA or RNA synthesis. Alkaloids bind to tubulin and inhibit the formation of microtubules, causing metaphase arrest, and camptothecins inhibit topoisomerase. Others - induces cell death or differentiation.
The knock of the API sector is having a significant effect on the overall cancer API market growth. The Oncology API market has undergone immense changes due to supply chain disruption caused by COVID-19. COVID-19 has disrupted the pharmaceutical industry's production and supply chain.
The global oncology drugs market size was valued at 135.4 Billion in 2020 and is projected to reach 274.4 billion by 2030, registering a CAGR of 7.5% from 2021 to 2030.
免責事項
このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。